{"nctId":"NCT03469349","briefTitle":"Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB","startDateStruct":{"date":"2018-05-01","type":"ACTUAL"},"conditions":["Peripheral Arterial Diseases"],"count":366,"armGroups":[{"label":"Actovegin 1200 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Actovegin"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Actovegin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Has a history of stable intermittent claudication lasting more than 6 months before Screening.\n2. Has a diagnosis of peripheral arterial disease (PAD) (Code I70.2 according to the international classification of diseases-10th revision) Fontaine Stage IIB confirmed by ultrasound color duplex imaging.\n3. Has a resting Doppler ankle-brachial index of less than or equal to (\\<=) 0.9.\n4. Has intermittent claudication with initial claudication distance (ICD) less than (\\<) 200 meters.\n5. Is not newly diagnosed with PAD and has a history of stable PAD therapy for at least 2 weeks before Screening.\n\nExclusion Criteria:\n\n1. Has PAD Fontaine Stage III or IV (pain at rest, non-healing ulceration, or gangrene).\n2. Has evidence of nonatherosclerotic PAD.\n3. Has greater than (\\>) 25 percent (%) variability in absolute claudication distance (ACD) based on treadmill testing during the screening period.\n4. Has lower extremity arterial reconstruction (surgical or endovascular) or sympathectomy within 3 months before Screening.\n5. Is eligible for surgical/interventional reconstruction.\n6. Had a myocardial infarction or major cardiac surgery within 3 months before Screening.\n7. Has congestive heart failure (New York Heart Association Class III/IV).\n8. Has uncontrolled diabetes mellitus (glycosylated hemoglobin \\[HbA1c \\>9%\\]) or diabetic polyneuropathy.\n9. Has any other illness that significantly limits exercise capacity or other medical condition, including any psychiatric disorder that limits participation (in the judgement of the investigator).\n10. The subject has received any prohibited medication within 14 days before Randomization (Day 1)\n11. The subject is undergoing the supervised exercise training program by the time of Screening and is going to continue this program due to its effectiveness.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12","description":"ICD was the distance walked at the onset of claudication pain or pain-free walking distance. ICD was assessed using treadmill testing. A fixed load treadmill test was carried out at 3.0 kilometer per hour (km/h) with a 10 percent (%) grade.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21.99","spread":"9.286"},{"groupId":"OG001","value":"51.17","spread":"9.187"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in ICD at Weeks 2 and 24","description":"ICD was the distance walked at the onset of claudication pain or pain-free walking distance. ICD was assessed using treadmill testing. A fixed load treadmill test was carried out at 3.0 km/h with a 10% grade.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.58","spread":"8.131"},{"groupId":"OG001","value":"22.45","spread":"7.981"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.12","spread":"10.665"},{"groupId":"OG001","value":"60.63","spread":"10.614"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline in Absolute Claudication Distance (ACD) at Weeks 2, 12 and 24","description":"ACD was the distance at which claudication pain becomes so severe that the participant was forced to stop, also known as maximal walking distance. ACD was assessed using treadmill testing. A fixed load treadmill test was carried out at 3.0 km/h with a 10% grade. The investigator will record the distance from walking start to the point where the participant is unable to walk anymore.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"134.5","spread":"58.84"},{"groupId":"OG001","value":"137.1","spread":"72.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.61","spread":"30.781"},{"groupId":"OG001","value":"46.28","spread":"179.356"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30.05","spread":"50.530"},{"groupId":"OG001","value":"75.51","spread":"190.808"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36.37","spread":"71.834"},{"groupId":"OG001","value":"86.47","spread":"227.491"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Rest Pain at Weeks 12 and 24","description":"Rest pain was defined as a continuous burning pain, that begins, or is aggravated, after reclining or elevating the limb and is relieved by sitting or standing.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":null},{"groupId":"OG001","value":"0.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Revascularization Procedures at Week 24","description":"Revascularization was defined by a Thrombolysis in Myocardial Infarction (TIMI) score of 2 or 3 following use of the Penumbra System. TIMI scores were used to describe blood flow at the treated vessel with 0 designating no flow and 3 for normal flow.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in 36-Item Short Form Survey (SF-36) at Weeks 12 and 24","description":"The SF-36 was a questionnaire that evaluated a participant's health related quality of life. SF-36 included 36 questions related to 8 health dimensions: physical functioning, role-physical (role limitations due to physical health problems), bodily pain, general health, vitality (energy/fatigue), social functioning, role-emotional (role limitations due to emotional problems), and mental health. Based on these 4 scales (physical functioning, role-physical, bodily pain, general health), the physical health score was generated which ranges between 0 and 100, with higher scores indicating a better quality of life. Based on these 4 scales (vitality, social functioning, role-emotional, and mental health), the mental health score was generated which ranges between 0 and 100, with higher scores indicating a better quality of life.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.533","spread":"6.3023"},{"groupId":"OG001","value":"39.905","spread":"6.5138"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.029","spread":"5.1633"},{"groupId":"OG001","value":"2.368","spread":"5.3725"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.752","spread":"6.1229"},{"groupId":"OG001","value":"2.333","spread":"5.1950"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.961","spread":"9.4891"},{"groupId":"OG001","value":"47.531","spread":"9.8667"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.134","spread":"7.2459"},{"groupId":"OG001","value":"2.434","spread":"8.2234"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.571","spread":"8.6698"},{"groupId":"OG001","value":"3.063","spread":"9.0286"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":182},"commonTop":["Nasopharyngitis","Diabetes mellitus","Pneumonia","Pyelonephritis chronic","Respiratory tract infection"]}}}